GlassScriptPhysician profile
James A Daly
NPI 1003884669
$11,643.80
in general payments reported to CMS, 2019-2025
41 companies · $2,177 in 2025
The $2,177 reported for 2025 was more than what 88% of Sleep Medicine (Internal Medicine) providers received nationally (typical 2025 total: $447).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,280 · 2020: $1,183 · 2021: $1,578 · 2022: $1,564 · 2023: $1,687 · 2024: $2,175 · 2025: $2,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,957 · Education: $81.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,956.57 |
| Education | $81.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,801.08 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Inspire Medical Systems, INC. | $1,243.83 | 2019-2025 | Inspire |
| Astrazeneca Pharmaceuticals LP | $1,008.38 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Harmony Biosciences LLC | $941.48 | 2020-2025 | Wakix |
| Jazz Pharmaceuticals INC. | $768.12 | 2019-2024 | |
| Grifols USA, LLC | $651.77 | 2020-2025 | Prolastin-C Liquid |
| Axsome Therapeutics, INC. | $497.88 | 2023-2025 | Sunosi |
| Genzyme Corporation | $447.30 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $416.92 | 2019-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $399.21 | 2019-2025 | Winrevair, Zerbaxa, Belsomra |
| Avadel Cns Pharmaceuticals, LLC | $343.14 | 2023-2025 | Lumryz |
| Actelion Pharmaceuticals US, INC. | $287.67 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.47 | 2019-2023 | Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $251.01 | 2020-2024 | Acthar |
| Insmed, INC. | $250.92 | 2020-2024 | Arikayce |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $243.51 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $195.14 | 2024-2025 | Glassia |
| Amgen INC. | $182.87 | 2021-2025 | Tezspire |
| Pulmonx Corporation | $175.10 | 2023-2025 | Zephyr Endobronchial Valve, Zephyr Delivery Catheter, Chartis Catheter |
| Mylan Specialty L.P. | $168.28 | 2019-2024 | Yupelri |
| United Therapeutics Corporation | $143.59 | 2021-2025 | Tyvaso, Tyvaso |
| Sunovion Pharmaceuticals INC. | $132.09 | 2019-2020 | |
| Optinose US, INC. | $113.27 | 2019-2021 | |
| Fisher & Paykel Healthcare INC | $101.22 | 2019-2024 | Fisher & Paykel Healthcare |
| Genentech USA, INC. | $96.44 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $76.04 | 2022-2025 | Quviviq, Quviviq |
| Inari Medical, INC. | $68.81 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Viatris Specialty LLC | $56.50 | 2025 | Yupelri |
| Verona Pharma, INC. | $49.25 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $43.66 | 2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $37.71 | 2021-2023 | Airduo Digihaler |
| Circassia INC. | $26.69 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $20.01 | 2024 | Purified Cortrophin Gel |
| Pharming Healthcare, INC. | $18.06 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.66 | 2022 | |
| Resmed Corp | $17.58 | 2022 | |
| Baxter Healthcare | $14.61 | 2023 | Hillrom - Life 2000 Ventilation System |
| Bayer Healthcare Pharmaceuticals INC. | $14.36 | 2025 | |
| Janssen Pharmaceuticals, INC | $12.63 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.29 | 2019 | |
| Ethicon INC. | $11.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Daly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.